EREBRAL cavernous malformations affect more than one in 200 individuals in the general population, exposing them to a lifetime risk of hemorrhagic stroke and epilepsy.
Abbreviations used in this paper: AVM = arteriovenous malformation; CCM = cerebral cavernous malformation; CNS = central nervous system; CSF = cerebrospinal fluid; Ig = immunoglobulin. in low-pH citrate buffer. Lymphoid tissue (tonsil) was used as a positive control. Negative controls included sections of CCM that had not been incubated with antibodies. Antibody dilutions of 1:50 were used according to the manufacturer's specifications.
Peripheral blood (15-20 ml) was collected by venipuncture, allowed to clot, and serum was separated by standard methods. Fragments of five surgically excised CCMs and three surgically excised AVMs (100-200 mg) as well as four control samples of normal brain (100-200 mg, including cerebral cortex and veins and arteries near the sylvian fissure) obtained at autopsy were thoroughly rinsed with saline and snap-frozen in liquid nitrogen. Samples were homogenized in Tris-buffered saline (pH 7.5). Protein concentrations were measured using the Quick Start Bradford protein assay (Bio-Rad Laboratories, Inc.). Isoelectric focusing was performed using Sebia Hydragel 9 CSF isoelectric focusing gels (pH 6-8) and a Hydrasys isofocusing system (Sebia, Inc.). Homogenized lesions and sera were diluted to an IgG concentration of 2 mg/dl, and 10-l samples were applied onto the gels and electrophoresed at 1000 V. Immunofixation was performed with antiserum to IgG according to kit instructions, and the gels were stained with acidic dimethylformamide (TTF3). Oligoclonal bands were defined as two or more distinct bands, as assessed by an immunopathologist experienced in this technique (I.J.C.) and blinded as to the origin of the specific sample.
Results
The results of immunohistochemical studies demonstrated B cells in all three lesions, and plasma cells in two out of three lesions examined. The CD20-stained sections from CCM lesions showed brown staining for B lymphocytes in a pericavernous cuffing pattern and scattered in the intercavernous matrix (Fig. 1) . The CD138-stained sections revealed multiple clusters of plasma cells near capillaries in the intercavernous matrix (Fig. 2) .
Four of five extracts of homogenized CCM lesions showed an oligoclonal banding pattern of IgG, as compared with the polyclonal pattern found in the corresponding respective sera, consistent with the origin of the defined IgG bands within the lesions (Fig. 3) . A fifth CCM lesion showed a polyclonal IgG pattern, as did the corresponding serum. All three AVM lesions showed polyclonal IgG, as did their corresponding sera, indicating no evidence of intralesional synthesis of IgG. Polyclonal patterns of IgG were also found in all four control brain specimens. In two of these cases (Autopsy 1 and 2), the sera showed polyclonal IgG; in one case of multiple myeloma (Autopsy 3) and in one of multiple organ failure following coronary bypass surgery (Autopsy 4), the sera showed oligoclonal IgG banding. In these cases, the bands seen in serum were not present in the brain specimens.
Discussion
Macrophage inflammatory cells have long been recognized to infiltrate CCM lesions, especially in reaction to acute bleeding.
14 Macrophages were also recently noted in histological analysis of the first CCM lesions produced in transgenic mice (Ccm1 ϩրϪ Trp53 ϪրϪ ). 9 Nevertheless, the presence of other inflammatory cells, especially those involved in an antigenic response has not, to our knowledge, been examined previously in these lesions. Our findings of B cells and plasma cells in CCM lesions provide preliminary evidence for the existence of an intralesional humoral immune response. The preliminary observations of antibody-producing cells in a limited number of lesions will need to be confirmed in a larger number of cases, with specific correlation to recent lesion behavior. Such a study is already underway in our laboratory. The findings reported in the current study and previous results showing upregulation of several Ig genes 11 in CCM lesions motivate us to further investigate the nature of this immune response. The demonstration of IgG of restricted heterogeneity within CCM lesions suggests that the immune response is produced by a limited number of plasma cell clones.
Oligoclonal IgG bands can be identified in the CSF of patients with a variety of infectious and inflammatory conditions involving the nervous system. These include multiple sclerosis, acute disseminated encephalomyelitis, Guillain-Barré syndrome, subacute sclerosing panencephalitis, progressive rubella panencephalitis, and acute viral encephalitis. 12 Oligoclonal IgG bands are also present in the CSF of a number of patients with structural CNS lesions, in whom no evidence for an infectious or inflammatory condition affecting the CNS can be found. 1 Oligoclonal IgG bands are also detected in cases of acute subarachnoid hemorrhage and stroke, often in both CSF and blood from these patients, probably representing a systemic response to these diseases. 13 In addition, oligoclonal bands have also been described specifically in the CSF of patients with spinal dural arteriovenous fistulae, frequently associated with venous hypertension myelopathy. To our knowledge, oligoclonal IgG bands have never been reported in cerebrovascular lesions themselves.
The clinical course of CCMs remains highly unpredictable because biological mechanisms underlying proliferative lesion phenotypes have not been elucidated. This is the first documentation of oligoclonal IgG in CCM lesions. The CCM lesions probably contain a significant amount of thrombus at various stages of organization in sequestered caverns. Although some of the lesional thrombus may simply reflect peripheral blood contamination, there may be differences in the gamma globulin composition within CCMs and peripheral blood, including the particular Igs associated with sequestered thrombus. The absence of identical oligoclonal bands in paired sera from the same cases effectively excludes blood contamination as a source of the intralesional oligoclonal IgG and suggests focal synthesis in the CCM lesions.
Oligoclonal IgG was absent in AVMs, which are phenotypically discrete cerebrovascular abnormalities. The AVMs indeed lack the leaky endothelial cell layer and repetitive hemorrhages associated with CCM, or the clustering of organized clot in brain parenchyma. 13, 16 Such features of CCMs may reflect the characteristic immune response apparently associated with CCM but not with AVM. The absence of IgG oligoclonality in brain AVMs appears to contradict a previous report of CSF oligoclonal bands in three of 11 patients with spinal AVMs, 1 but this difference in findings is probably due to the different nature of spinal AVMs and cerebral AVMs. Spinal AVMs indeed represent dural fistulae and cause ischemic myelopathy from secondary venous hypertension, and associated CSF oligoclonal bands could reflect this secondary myelopathy. Oligoclonal IgG has never been reported in AVM lesions themselves.
Oligoclonal IgG bands were also absent from normal brain and blood vessels in four control cases, even when they were present in the serum in two of these cases. Their presence in the serum was probably due to the specific B-cell clonal expansion in one patient with multiple myeloma, and to inflammation from multiple organ dysfunction after coronary bypass surgery in the second patient. The absence of the oligoclonal IgG bands in these patients' brains was probably due to the integrity of their bloodbrain barrier.
The demonstration of oligoclonal IgG in four of five CCM lesions provides evidence for a characteristic focal immune response. A focal immune response with Ig oligoclonality has been associated with abnormal vascular proliferation in a number of pathological conditions. 5, 6, 8 An IgG response to infection is associated with proliferative hemorrhagic capillaries, similar in histological characteristics to CCMs. 7 The apparent local synthesis and oligoclonality of IgG in CCM lesions probably suggests clonal expansion of B cells and/or plasma cells in CCM lesions, an event that might be antigen-driven. The CCM phenotype predisposes to vascular leakage and accumulation of blood products in adjacent brain tissue. This phenomenon may create a special milieu for antigenic challenge and immune response and in turn contribute to lesion proliferation and clinical manifestations.
The sequestered blood and chronic accumulation of blood breakdown products within CCM lesions may be the trigger of this humoral immune response. The blood from acute brain hemorrhages is absorbed over time, and may not have an opportunity to trigger a similar response. Wasserman and Schlichter 15 examined the inflammatory response to intracerebral hemorrhage in a rat model, and described microglial and macrophage infiltration but no antibody-producing B cells or plasma cells. A unique aspect of CCM lesions is repetitive hemorrhage, which results in longstanding deposition of blood products as well as the presence of sequestered blood in caverns. These features may be responsible, in part, for the immune response that we observed. The question of whether an oligoclonal immune response is evoked in relation to the duration and type of blood product deposition in the brain should be examined in future studies.
A focal immune response in CCMs could explain, in part, why some CCM lesions remain biologically dormant, whereas others proliferate with serious clinical consequences. Or it could represent a reaction to and potential marker of lesion proliferation and hemorrhage. Studies are underway in our laboratory, with an aim of correlating inflammatory response in CCM with recent lesion proliferation and hemorrhage. Future studies are planned to confirm oligoclonality of the immune reponse by assessing the distribution of lengths of the third complementarity-determining regions (CDR3s) of the Ig heavy-chain genes in mRNA isolated from pooled plasma cells and B cells laser-captured from CCMs, in comparison with peripheral lymphocytes from the blood of the same patients. Identification of an autoimmune or extrinsic antigenic trigger could possibly con- tribute to the understanding of disease progression, leading to better diagnosis and treatment of patients with CCM disease.
Conclusions
Because macrophages have already been found in CCM lesions, we searched for other cells that may contribute to inflammation within CCMs. Our discovery that B cells and plasmacytes are present within CCM lesions suggests an oligoclonal humoral immune response within CCMs. A more systematic analysis of inflammatory cell distribution in these lesions is already underway in our laboratory, including correlation with recent lesion behavior. We demonstrated, by isoelectric focusing, that there are indeed oligoclonal patterns of IgG in CCM lesions that are independent of peripheral blood contamination. These findings, which indicate selective production of IgG within the lesions, constitute the first demonstration of oligoclonal IgG in CCMs. This possible local clonal expansion of B cells and/or plasma cells in CCMs might be an antigen-driven event. A partial explanation for why some CCM lesions remain biologically quiescent whereas others proliferate with grave clinical consequences may result from the specific characteristics of this immune response. This immune response could also be a reaction to and potential marker of lesion proliferation and hemorrhage in CCMs. Future work may lead to identification of the antigenic trigger for the characteristic immune response in CCMs. 
